trial · primary record
Olutasidenib Investigational Agent Administration
Acute Myeloid Leukemia
| Phase | Phase 1 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | Not stated |
| Primary completion | 2030-10-31 |
| Primary endpoint | Assess the feasibility of olutasidenib after upfront acute myeloid leukemia (AML) therapy with intensive induction and/or consolidation in IDH1 mutant AML. |
| Registry ID | NCT07130695 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:33:36.503Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07130695
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.